NCT02690701

Trial name or title	Study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects with moderate to severe plaque psoriasis (VIP‐S)
Methods	RCT, placebo‐controlled, double‐blind study Date of study: February 2016 ‐ Location: USA Phase 4
Participants	Randomised: 84 participants Inclusion criteria Men and women ≥ 18 years with moderate‐severe plaque psoriasis Exclusion criteria Forms of psoriasis other than chronic plaque psoriasis Previous exposure to IL‐17A or IL‐17 receptor targeting agents Other active or ongoing disease that may interfere with evaluation of psoriasis or places the participant at unacceptable risk
Interventions	Intervention Secukinumab 300 (300 mg once weekly at baseline, weeks 1, 2, 3 and 4 followed by monthly dosing starting at week 8 through week 48 inclusive) Control intervention Placebo
Outcomes	At week 12 Primary outcome Aortic vascular inflammation as measured by FDG‐PET/CT Secondary outcomes PASI 75 PASI 90 PASI 100 IGA 0/1 DLQI
Starting date	Study start date: February 2016 Study completion date: March 2018
Contact information	Novartis Pharmaceuticals, 1‐888‐669‐6682
Notes	Ongoing study